Florida Hospital Tampa Presents Results for Landmark Clinical Trial Using Stem Cell Therapy on Heart Attack Patients

Share Article

Florida Hospital Tampa is leading the way in clinical research by using stem cells to repair damaged hearts. The results of the clinical trial TIME, show therapy with bone marrow-derived stem cells does not improve short-term recovery after a heart attack.

Now, with both TIME and LateTime, we have baseline results. The clinical trial conclusions play a critical role in helping us take the next step in stem cell therapy research, said Dr. Charles Lambert.

Florida Hospital Pepin Heart Institute has participated in two landmark studies that provide answers, giving researchers new information to move forward in heart stem cell therapy research. The clinical trial, called Transplantation In Myocardial Infarction Evaluation (TIME), was designed to see if heart function would improve by administering stem cells derived from the patient’s own bone marrow either three or seven days after a heart attack. The results show therapy with bone marrow-derived stem cells does not improve short-term recovery after a heart attack.

The results mirror a previous, related study called LateTIME. The LateTime study found that cells which come from the patients (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function. Both TIME and LateTime were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN). Florida Hospital Pepin Heart Institute and the Dr. Kiran C. Patel Research Institute are members of the CCTRN.
Dr. Charles Lambert, Medical Director of Florida Hospital Pepin Heart Institute, is the site’s principal investigator for the trial and co-author of the JAMA article. The findings from the TIME clinical trial will be presented this month at the American Heart Association 2012 Scientific Sessions in Los Angeles and published in the Journal of the American Medical Association (JAMA).

“The TIME study was extremely important because it answered the question, will the bone marrow-derived stem cells improve short-term recovery…and the answer is no. Now, with both TIME and LateTime, we have baseline results. The clinical trial conclusions play a critical role in helping us take the next step in stem cell therapy research,” said Dr. Lambert.

The TIME study researchers enrolled about 120 volunteers between July 2008 and February 2011. The participants suffered from moderate to severe impairment in their left ventricles and had undergone stenting procedures following heart attacks. Heart improvements were assessed six months after stem cell therapy by measuring the percentage of blood that was pumped out of the left ventricle during each contraction.

Now with the baseline set, researchers can adjust some of the components to grow and administer stem cell to find cases where the procedure may improve function. For example, researchers believe this therapy may work better in different population groups, or during new methods of delivery. Another advantage of the TIME study is that CCTRN will store samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study.

Heart attack patients from the TIME study will continue to be followed here at Florida Hospital Pepin Heart Institute for at least a year to monitor any late changes in cardiac function. Although no significant improvement was recorded with heart attack patients in the Late-TIME trial, Dr. Lambert says the work that went into collecting patient data over the past years is very useful for the National Institutes of Health stem cell researchers.

“Well-controlled trials such as this are very important in determining whether therapies are actually effective and we will continue to design and test new cell treatment strategies with scientists in the CCTRN,” says Dr. Lambert. Other members of the study’s Cardiac Cell Therapy Research Network include the University of Florida, Vanderbilt University, the Texas Heart Institute, the Cleveland Clinic and the Mayo Clinic.

About Florida Hospital Tampa
Florida Hospital Tampa is a not-for-profit 475-bed tertiary hospital specializing in cardiovascular medicine, neuroscience, orthopaedics, women’s services, pediatrics, oncology, endocrinology, bariatrics, wound healing, sleep medicine and general surgery including minimally invasive and robotic-assisted procedures. Also located at Florida Hospital Tampa is the renowned Florida Hospital Pepin Heart Institute, a recognized leader in cardiovascular disease prevention, diagnosis, treatment and leading-edge research. Part of the Adventist Health System, Florida Hospital is a leading health network comprised of 22 hospitals throughout the state. For more information, visit http://www.FHTampa.org.

About Florida Hospital Pepin Heart Institute and Dr. Kiran C. Patel Research Institute
Florida Hospital Pepin Heart Institute is a free-standing cardiovascular institute providing comprehensive cardiovascular care with over 76,000 angioplasty procedures and 11,000 open-heart surgeries in the Tampa Bay region. Leading the way with the first accredited chest pain emergency room in Tampa Bay, the institute is among an elite few in the state of Florida chosen to perform the ground breaking Transcatheter Aortic Valve Replacement (TAVR) procedure. It is also a HeartCaring designated provider and a Larry King Cardiac Foundation Hospital. Florida Hospital Pepin Heart Institute and the Dr. Kiran C. Patel Research Institute, affiliated with the University of South Florida (USF), are exploring and conducting leading-edge research to develop break-through treatments long before they are available in most other hospitals. To learn more, visit http://www.FHPepin.org.

FHT-1018PR

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jennifer McVan
Visit website